Why Humacyte (HUMA) Shares Are Falling

Humacyte Inc HUMA shares are trading lower by 29.2% to $3.08 during Friday’s session after the company announced pricing of a $40.2 million public offering of common stock.

Humacyte priced its underwritten public offering of 13.4 million shares of common stock at $3.00 per share. The offering is expected to close on March 5, pending customary closing conditions. Additionally, the underwriters have an option to purchase up to an additional 2.01 million shares within 30 days.

The proceeds will be used for advancing its regenerative medicine pipeline, supporting FDA review of its Biologics License Application for bioengineered human acellular vessels, establishing commercial infrastructure, and general corporate purposes.

TD Cowen and Cantor are joint book-running managers, with BTIG as the lead manager for the offering.

See Also: Netflix’s 2024 Gains Are Cinema’s Loss

How To Buy HUMA Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Humacyte’s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, HUMA has a 52-week high of $5.60 and a 52-week low of $1.96.